A Single-Center Retrospective Study to Compare the Efficacy and Safety of Modified FOLFIRINOX with S-1 as Adjuvant Chemotherapy in 71 Patients with Resected Pancreatic Carcinoma

Linhua Yao; Chengwu Tang; Wenming Feng; Hanbin Dai

doi:10.12659/MSM.937136

20 June 2022: Clinical Research

A Single-Center Retrospective Study to Compare the Efficacy and Safety of Modified FOLFIRINOX with S-1 as Adjuvant Chemotherapy in 71 Patients with Resected Pancreatic Carcinoma

Linhua Yao ^1ABCEF , Chengwu Tang ^2ABCEF , Wenming Feng ^2ABFG , Hanbin Dai ^2ABCE*

DOI: 10.12659/MSM.937136

Med Sci Monit 2022; 28:e937136

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

View HTML version

Figure 1 Comparison of relapse-free survival. Relapse was confirmed in 23 patients of the mFFX group and 26 patients of the S-1 group within 3 years postoperatively. The mFFX group demonstrated a markedly higher 3-year relapse-free survival (P=0.0332) and lower hazard ratio for relapse (0.5577, 95% CI, 0.3138 to 0.9910) than the S-1 group. MedCalc software (version 15.2.2, MedCalc Software, Ltd.) was used to create the figure.

Back to the Article

A Single-Center Retrospective Study to Compare the Efficacy and Safety of Modified FOLFIRINOX with S-1 as Adjuvant Chemotherapy in 71 Patients with Resected Pancreatic Carcinoma

Your Privacy